{
    "ticker": "AFMD",
    "name": "Avidity Biosciences, Inc.",
    "description": "Avidity Biosciences, Inc. is a biotechnology company focused on revolutionizing the treatment of diseases by utilizing its proprietary Avidity Technology\u2122 to create a new class of therapeutics called Antibody Oligonucleotide Conjugates (AOCs). Founded in 2012 and headquartered in La Jolla, California, Avidity aims to leverage the power of antibodies to deliver oligonucleotides directly to the target tissues, thereby improving the efficacy and safety profiles of RNA-targeted therapies. The company is pioneering the development of AOCs for a range of diseases, including genetic disorders and certain types of cancer. Avidity's lead product candidate, AOC 1001, is being developed for the treatment of myotonic dystrophy type 1 (DM1), a severe genetic disorder. With a robust pipeline of AOC candidates, Avidity is committed to advancing innovative therapies that have the potential to transform patients' lives. The company's mission is to harness the power of its technology platform to address significant unmet medical needs and create safe and effective treatment options for patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "La Jolla, California, USA",
    "founded": "2012",
    "website": "https://www.aviditybiosciences.com",
    "ceo": "Sarah Boyce",
    "social_media": {
        "twitter": "https://twitter.com/AvidityBio",
        "linkedin": "https://www.linkedin.com/company/avidity-biosciences/"
    },
    "investor_relations": "https://investors.aviditybiosciences.com",
    "key_executives": [
        {
            "name": "Sarah Boyce",
            "position": "CEO"
        },
        {
            "name": "Jeffrey A. Karp",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "AOC 1001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Avidity Biosciences, Inc. | Innovative Biotechnology Solutions",
        "meta_description": "Explore Avidity Biosciences, a leader in developing Antibody Oligonucleotide Conjugates for treating genetic disorders and cancers. Discover our innovative approach and pipeline.",
        "keywords": [
            "Avidity Biosciences",
            "Antibody Oligonucleotide Conjugates",
            "Biotechnology",
            "RNA-targeted therapies",
            "Genetic Disorders",
            "Cancer Therapies"
        ]
    },
    "faq": [
        {
            "question": "What is Avidity Biosciences known for?",
            "answer": "Avidity Biosciences is known for its innovative Antibody Oligonucleotide Conjugates (AOCs) aimed at treating genetic disorders and cancers."
        },
        {
            "question": "Who is the CEO of Avidity Biosciences?",
            "answer": "Sarah Boyce is the CEO of Avidity Biosciences, Inc."
        },
        {
            "question": "Where is Avidity Biosciences headquartered?",
            "answer": "Avidity Biosciences is headquartered in La Jolla, California, USA."
        },
        {
            "question": "What are the main products of Avidity Biosciences?",
            "answer": "The main product candidate is AOC 1001, which is under development for myotonic dystrophy type 1."
        },
        {
            "question": "When was Avidity Biosciences founded?",
            "answer": "Avidity Biosciences was founded in 2012."
        }
    ],
    "competitors": [
        "SRPT",
        "AMGN",
        "PFE",
        "VRTX"
    ],
    "related_stocks": [
        "MRNA",
        "BMRN",
        "BLUE",
        "REGN"
    ]
}